Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Belimumab in Primary Sjögren's Syndrome

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Are at least 18 years of age.~2. Have a diagnosis of primary SS according to the updated American European Consensus Group Criteria -~Exclusion Criteria:~1. Have received treatment with any BLyS-targeted (BLyS-receptor fusion protein \[BR3\], TACI Fc, or belimumab) at any time.~2. Have a Grade 3 or greater laboratory abnormality based on the protocol toxicity scale except for the following that are allowed:~   * Stable Grade 3 prothrombin time (PT) secondary to warfarin treatment.~  * Stable Grade 3/4 proteinuria (≤ 6 g/24 hour equivalent by spot urine protein to creatinine ratio allowed).~  * Stable Grade 3 neutropenia or stable Grade 3 white blood cell count

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- single arm (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).